These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 37476983)
1. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib. Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983 [TBL] [Abstract][Full Text] [Related]
2. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia. Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Jacobs R Patient Prefer Adherence; 2023; 17():2073-2084. PubMed ID: 37641660 [TBL] [Abstract][Full Text] [Related]
3. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Byrd JC; Hillmen P; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Yenerel MN; Illés A; Kay N; Garcia-Marco JA; Mato A; Pinilla-Ibarz J; Seymour JF; Lepretre S; Stilgenbauer S; Robak T; Rothbaum W; Izumi R; Hamdy A; Patel P; Higgins K; Sohoni S; Jurczak W J Clin Oncol; 2021 Nov; 39(31):3441-3452. PubMed ID: 34310172 [TBL] [Abstract][Full Text] [Related]
4. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis. Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204 [TBL] [Abstract][Full Text] [Related]
5. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Miao Y; Xu W; Li J Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844 [TBL] [Abstract][Full Text] [Related]
7. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Woyach JA; Jones D; Jurczak W; Robak T; Illés Á; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V Blood; 2024 Sep; 144(10):1061-1068. PubMed ID: 38754046 [TBL] [Abstract][Full Text] [Related]
8. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors. Thompson MC; Mato AR Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986 [TBL] [Abstract][Full Text] [Related]
10. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Roeker LE; DerSarkissian M; Ryan K; Chen Y; Duh MS; Wahlstrom SK; Hakre S; Yu L; Guo H; Mato AR Blood Adv; 2023 Aug; 7(16):4291-4301. PubMed ID: 37163361 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907 [No Abstract] [Full Text] [Related]
13. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891 [TBL] [Abstract][Full Text] [Related]
14. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis. Nunes RAB; Avezum Á; de Oliveira Marques M; Baiocchi OCCG; Bachour P Ann Hematol; 2024 Nov; 103(11):4613-4620. PubMed ID: 39153144 [TBL] [Abstract][Full Text] [Related]
15. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Wolska-Washer A; Robak T Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194 [TBL] [Abstract][Full Text] [Related]
16. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. Danilov AV; Persky DO Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986 [TBL] [Abstract][Full Text] [Related]
17. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. Egyed M; Lueff S; Borbely J; Illes A Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644 [TBL] [Abstract][Full Text] [Related]
18. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679 [No Abstract] [Full Text] [Related]
19. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255 [TBL] [Abstract][Full Text] [Related]
20. An update on acalabrutinib to treat chronic lymphocytic leukemia. Blackmon A; O'Brien S Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]